338 related articles for article (PubMed ID: 29668586)
21. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.
Sölétormos G; Duffy MJ; Othman Abu Hassan S; Verheijen RH; Tholander B; Bast RC; Gaarenstroom KN; Sturgeon CM; Bonfrer JM; Petersen PH; Troonen H; CarloTorre G; Kanty Kulpa J; Tuxen MK; Molina R
Int J Gynecol Cancer; 2016 Jan; 26(1):43-51. PubMed ID: 26588231
[TBL] [Abstract][Full Text] [Related]
22. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
[TBL] [Abstract][Full Text] [Related]
23. The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer.
Yang ZJ; Zhao BB; Li L
J Ovarian Res; 2016 Sep; 9(1):57. PubMed ID: 27629537
[TBL] [Abstract][Full Text] [Related]
24. Preoperative measurement of serum C-reactive protein: is it useful in the differential diagnosis of adnexal masses?
Yoshida A; Derchain SF; Pitta DR; Crozatti N; Andrade LALA; da Silva RF; Sarian LO
Int J Biol Markers; 2017 Mar; 32(1):e83-e89. PubMed ID: 27516000
[TBL] [Abstract][Full Text] [Related]
25. Comparison of risk of malignancy index (RMI), CA125, CA 19-9, ultrasound score, and menopausal status in borderline ovarian tumor.
Alanbay I; Akturk E; Coksuer H; Ercan M; Karaşahin E; Dede M; Yenen MC; Ozan H; Baser I
Gynecol Endocrinol; 2012 Jun; 28(6):478-82. PubMed ID: 22122561
[TBL] [Abstract][Full Text] [Related]
26. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
[TBL] [Abstract][Full Text] [Related]
27. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
29. Pre-operative evaluation of ovarian tumors by risk of malignancy index, CA125 and ultrasound.
Arun-Muthuvel V; Jaya V
Asian Pac J Cancer Prev; 2014; 15(6):2929-32. PubMed ID: 24761927
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
31. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
Lycke M; Kristjansdottir B; Sundfeldt K
Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the importance of the serum levels of CA-125, CA15-3, CA-19-9, carcinoembryonic antigen and alpha fetoprotein for distinguishing benign and malignant adnexal masses and contribution of different test combinations to diagnostic accuracy.
Bozkurt M; Yumru AE; Aral I
Eur J Gynaecol Oncol; 2013; 34(6):540-4. PubMed ID: 24601047
[TBL] [Abstract][Full Text] [Related]
33. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
[TBL] [Abstract][Full Text] [Related]
34. [Potential value of CA125 kinetic monitoring in the initial management of advanced epithelial ovarian cancer].
Vignot S; Brochet C; Debord C; Lauratet B; Bernard M
Ann Biol Clin (Paris); 2011; 69(5):597-604. PubMed ID: 22008142
[TBL] [Abstract][Full Text] [Related]
35. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses.
Moro F; Pasciuto T; Djokovic D; Di Legge A; Granato V; Moruzzi MC; Mancari R; Zannoni GF; Fischerova D; Franchi D; Scambia G; Testa AC
Ultrasound Obstet Gynecol; 2019 Jan; 53(1):116-123. PubMed ID: 29978587
[TBL] [Abstract][Full Text] [Related]
36. Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology.
Han L; Pansare V; Al-Abbadi M; Husain M; Feng J
Diagn Cytopathol; 2010 May; 38(5):333-6. PubMed ID: 19856421
[TBL] [Abstract][Full Text] [Related]
37. [Diagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
Bendifallah S; Body G; Daraï E; Ouldamer L
Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):134-154. PubMed ID: 30733191
[TBL] [Abstract][Full Text] [Related]
38. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
39. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125.
Li W; Wang D
Arch Gynecol Obstet; 2020 May; 301(5):1219-1225. PubMed ID: 32266526
[TBL] [Abstract][Full Text] [Related]
40. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]